Introduction

Colorectal cancer
Colorectal cancer (CRC) is the third most common cancer diagnosed in the United States and is the third leading cause of cancer-related deaths. 1 There is a progressive worse overall survival for patients with advancing stages of disease. The relative 5-year survival for stage I CRC is 92%. The 5-year survival for stage IIA and Stage IIB are 87% and 63%, respectively. The 5-year survival for stage IIIA, Stage IIIB and stage IIIC are 89%, 69% and 53%, respectively. The 5-year survival for stage IV disease is 11%. Most patients present with latestage disease and the 5-year survival for patients with newly diagnosed metastatic CRC is low. 2 The underlying etiology of CRC is complex and heterogeneous. There are three distinct pathways of pathogenesis that underlie the development of colorectal carcinogenesis; chromosomal instability, microsatellite instability and the CpG island methylator phenotype. However, a central mechanism through which cancer cells develop metastatic potential is EMT.
Epithelial-mesenchymal transition
EMT is the process whereby cells lose their morphological and functional epithelial features and gain a mesenchymal phenotype, through differential gene overexpression and repression. 3, 4 Zinc-finger E-box binding homeobox 1 (ZEB1) is a crucial component of EMT which alters the expression of cellular adhesion proteins such as E-cadherin and cellular polarity factors. EMT is recognized to be one of the most critical steps in the development of tumor metastasis. The change to a mesenchymal phenotype promotes increased cellular motility and migration, and therefore tumor metastasis. Investigation into the molecular pathways and mechanisms involved is important to facilitate the understanding of tumor biology and the creation of new novel and targeted therapies.
MicroRNAs
MicroRNAs (miRs) have a major role in the regulation of cell function through specific interaction with messenger RNA (mRNA) to inhibit protein translation. miRs are small, naturally occurring, nonprotein coding RNA molecules that are approximately 20 nucleotides in length. miRs are transcribed in the nucleus as large RNA precursors called primary microRNAs. 5 Through subsequent processing in the nucleus and transportation to the cytoplasm by the enzymes Drosha, exportin 5, DICER and argonaute 2, mature doublestranded microRNA are formed. 6, 7 While microRNAs have several normal functions related to cell growth, development and differentiation, aberrant expression of these microRNAs may contribute to tumorigenesis. 8 Furthermore, altered expression of microRNAs in tumor tissue or serum may have a role in the diagnosis of patients with CRC. As a result of this bidirectional repression, a feed-forward loop is established resulting in the expression of an epithelial or mesenchymal phenotype depending on the initial signal. 3, 4, 12 A number of reviews have separately described the role of the miR-200 family in different cancers and have described the role of microRNAs in CRC but this is the first systematic review to describe the role of the miR-200 family solely in CRC. [13] [14] [15] This is of particular interest in CRC as TP53, which is frequently mutated in CRC, is known repress EMT by the expression of the miR-200 family. 16, 17 We sought to perform a systematic review of available data regarding both in vitro and in human studies pertaining to the function of the miR-200 family in CRC. We wished to identify the involved molecular mechanisms, and identify possible potential diagnostic, prognostic and therapeutic applications for use in patients with CRC.
Methods
Our study was conducted using the "Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines." 18, 19 Two reviewers (S.J.O'B and J.V.C) were involved in study selection and analysis. The electronic PubMed (NCBI, Bethesda, MD) and EMBASE (Elsevier, Amsterdam, The Netherlands) databases were searched for relevant articles published between January 1, 2000 and July 31, 2017 using the following medical subject heading (MESH) terms and Boolean logic terms; ("MicroRNA-200" OR "miRNA-200" OR "miR-200" OR "MicroRNA-200a" OR "miRNA-200a" OR "miR-200a" OR "MicroRNA-200b" OR "miRNA-200b" OR "miR-200b" OR "MicroRNA-200c" OR "miRNA-200c" OR "miR-200c" OR "MicroRNA-141" OR "miRNA-141" OR "miR-141" OR "MicroRNA-429" OR "miRNA-429" OR "miR-429") AND ("Colorectal cancer" OR "Colorectal carcinoma" OR "Colorectal"). No language limitations were used. The searches from the databases were collated and duplicates removed. Articles for which the full text was not available were removed. Titles and abstracts served as an initial screen to determine relevance to the review topic. Articles of uncertain relevance were reviewed for a definitive decision. Other significant articles were identified from manual searches of the references of original and review papers.
Inclusion and exclusion criteria were developed by the investigative team. Human and in vitro studies examining the mechanistic pathway between the miR-200 family and CRC were included. Human studies examining the diagnostic, prognostic and therapeutic significance of the miR-200 family in patients with CRC were included in the review. The illustration depicting the EMT axis was modified from MetaCore v6.32 (Thomas Reuters), using the pathway maps and process networks functions. Nodes including the miR-200 family and depicting the EMT axis were included.
What's new?
A central mechanism through which cancer cells develop metastatic potential is epithelial-mesenchymal transition (EMT). The miR-200 family has a significant regulatory role in EMT in colorectal carcinogenesis, but its function remains to be clarified. This is the first systematic review to describe the molecular pathways involved and potential clinical applications of the miR-200 family solely in colorectal cancer. In vitro studies showed that the miR-200 family may have a role in improving chemosensitivity. Clinical studies identified the miR-200 family as a potential biomarker to predict patient outcomes. The miR-200 family has potential for both prognostic and therapeutic management of CRC.
Results
Initially, 123 records were identified from the database searches with an additional 14 records obtained from manual searches of individual studies. The search process is illustrated in Supporting Information Figure S1 . Total of 101 records remained after duplicates were removed. Thirty-eight records were excluded because they were irrelevant to the review topic. Sixty-three records were analyzed further for inclusion in the review. Twenty-nine articles were excluded due to reporting on cancers other than CRC (n 5 6), for being review papers/meta-analyses (n 5 13), studies of microRNAs other than the miR-200 family (n 5 7) or due to an inability to obtain the full length article (n 5 3). An illustration of the EMT axis is included in Figure 1 .
In vitro studies Epigenetic regulation and transcriptional factor regulation. The in vitro studies and the summary of their results are described in Table 1 . A number of studies have examined potential triggers for the switch to an epithelial or mesenchymal phenotype. Epigenetic regulation is a crucial part of determining the expression of miR-200 family. Methylation of the miR-200 family promoter regions led to repression of microRNA expression and subsequent mesenchymal marker expression (vimentin) in a number of CRC cell lines. 12 As expected, hypomethylation of the promoter regions, resulted in the re-expression of epithelial markers (E-Cadherin, Lethal giant larvae 2). 12 Interestingly, there is variable methylation of the miR-200 family promoter regions within a cell line (e.g., HCT116 miR-200b-429 promoter methylation-60.9%, miR-200c-141 promoter methylation-1.0%) and between cell lines (e.g., HCT116 miR-200b-429 promoter methylation-60.9%, RKO miR-200b-429 promoter methylation-0.9%). A number of groups have identified that treatment with a demethylating agent causes subsequent upregulation of miR-200b and miR-429 in hypermethylated cell lines. 20, 21 This reduced cellular invasion and migration. 21 Fessler et al. demonstrated epigenetic methylation of the miR-200 family promoter regions is associated with miR-200 family repression and a mesenchymal phenotype in a group of clinical samples. 22 However, the demethylating agents used are nonspecific for the miR-200 family, and while miR-200 expression levels expectedly increase following treatment, further investigation is required to associate a significant role for miR-200 family activation in subsequent cellular signalling and phenotypic changes. There is evidence of plasticity between the epithelial and mesenchymal phenotype. ASCL2 is a transcription factor that is over-expressed in CRC. ASCL2 is over-expressed in the HT29 cell line and caused repression of the two miR-200 clusters through direct binding to the common promoter regions and produced a mesenchymal phenotype. Subsequent knockdown of ASCL2 promoted mesenchymal-to-epithelial transition with re-expression miR-200 family. 23 Nanog is a transcription factor involved in embryonic stem cell renewal. Pan et al. demonstrated that it bound directly to the separate miR-200 promoter regions, repressing their transcription and resulting in a mesenchymal phenotype. 24 The identification and manipulation of transcription factors as an adjunct to promoting an epithelial phenotype could be investigated as it may have a therapeutic potential.
Other miR-200 family regulation. The use of microRNA target prediction programs (e.g., TargetScan v7.1: www.targetscan.org, mirdb: www.mirdb.org, TarBase v8.0: http://carolina. imis.athenainnovation.g/diana_tools/web/index.php?r 5tarbasev8%2Findex) and databases has identified other mechanisms through which the miR-200 family may work. SPROUTY-2 is regulator of tyrosine kinase receptor signalling and was found to downregulate genes involved in cellular adhesion. Barbachano et al. demonstrated that SPROUTY-2 upregulated the expression of ZEB1 both by repression of miR-200b and by induction of transcription factor ETS1. 25 As mentioned previously, DICER is an enzyme involved in the cytoplasmic processing and maturation of microRNAs. In DICER1 impairment in CRC cell lines, there was an expected downregulated expression of the miR-200 family with resulting expression of mesenchymal proteins. 26 Manipulation of microRNA processing factors warrants further research, as any manipulation will alter the production of all microRNAs, but this may have a major effect on tumor signaling. Sineoculis homeobox homolog 1 (SIX1) is a homeoprotein known to be involved in tumor initiation and progression. Overexpression of SIX1 in a number of CRC cell lines had associated repression of the miR-200 family, expression and ZEB1 and a mesenchymal phenotype. Interestingly, the authors demonstrated increased SIX1 expression at the invasive border of clinical samples, which highlights the role that it may have in EMT modulation. However, the mechanism Hu et al.
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Zhong et al. The transforming growth factor-b (TGF-b) pathway is a complex signaling cascade, which has both tumor suppressive and proliferative functions that may be regulated by the expression of TGFb receptor 2 (TGFBRII). While the miR-200 family is classically described in the ZEB1/E-cadherin pathway, there is an interesting differential expression noted between TGFBRII-expressive and deficient CRC cell lines. Burk et al. showed that miR-141 directly targets and represses TGF-b2, promoting an epithelial phenotype in a TGFBRII-expressive cell line. 3 Similarly, TGF-b1 induced cellular repression, with associated miR-200b repression in TGFBRII-expressive cell lines. 31 Conversely, TGF-b1 induces cellular proliferation in TGFBRII-deficient cell lines, with associated increased miR-200b. 32 This interesting dichotomous role for the miR-200 family may be mediated by TGFBRII expression. KRAS is a well described oncogene, which has been implicated in colorectal carcinogenesis. KRAS represses miR-200b and miR-200c in CRC cell lines with both wild-type and mutant KRAS. JUN and SP1 are transcription factors induced by KRAS, which target the miR-200 common promoter regions. 28 They could be potential downstream therapeutic targets molecules as some contemporary therapeutic agents are dependent on KRAS status for efficacy.
In contrast to the often cited tumor suppressive role of the miR-200 family in CRC, Pan et al. demonstrated a tumor proliferative role for miR-200b and miR-200c by direct binding of RECK mRNA (reversion-inducing-cysteine-rich protein with kazal motifs). This led to downsteam activation of SKP2 and CDKN1B, which promote tumor proliferation. 33 While this is only a single study, it highlights the fact that microRNAs can target multiple pathways and may have conflicting effects on tumor signaling.
Therapeutic Potential: miR-200 Family Changing Colon Cancer Cell Line Behavior
Migration/motility and variability between cell lines. While there is reduced expression of the miR-200 family in some cancer cell lines, associated with a mesenchymal phenotype, forced expression of the miR-200 family has been associated with reversion to an epithelial phenotype in some studies. Different mechanisms have been proposed by authors to explain the reduced cellular migration and motility. As previously mentioned, miR-141 targets the 3 0 UTR of SIP1 mRNA, and Hu et al. replicated this with miR-141 transfection into CRC cell lines (SW620). 27 Comparatively, transfection with miR-429 (in SW480, SW620, HT-29 and LoVo cell lines) was shown to target ONECUT2, a transcription factor involved in the expression of EMT-related genes, and induced similar cellular repression. 29, 40 In direct contrast to these results, transfection of miR-141 (in LoVo cell line) increased cellular migration, proliferation and growth. 30 Transfection of miR-200c (in RKO and SW620 cell lines) reduced cellular migration and invasion, but induced cellular proliferation. 20 There is significant variability seen in the response of different cell lines to transfection with different members of the miR-200 family and further study is warranted to elucidate these differences and the mechanisms for this variation.
Chemoresistance. Chemotherapeutic drug resistance is an important component in the treatment of CRC. Several studies have examined the role of the miR-200 family in chemotherapeutic-resistant CRC cell lines. As previously mentioned, methylation of the miR-200 promoter regions results in the repression of epithelial markers. 12, 21 In oxaliplatin-resistant SW620 cells, which display mesenchymal features, treatment with a demethylating agent resulted in the restoration of expression of miR-200c and miR-141 as well as the epithelial marker, E-cadherin. 35, 36 However, as previously mentioned, the demethylating agents used are not specific to the promoter regions of the miR-200 family, and other genes may be activated with demethylation and contribute to the phenotypic changes. It is hypothesized that repression of miR-200c and miR-141 was a marker for chemotherapy resistance. In a 5-fluorouracil-resistant SW620 model, direct treatment with a miR-200c mimic restored an epithelial phenotype and reduced the expression of mesenchymal markers including transcription factors SLUG1 and ZEB1. 37 Similarly, treatment with a miR-141 mimic in a 5-fluorouracil and oxaliplatintreated SW620 cell line led to reduced cell viability. 38 In a number of drug-resistant CRC cell lines, direct treatment with a miR-200c mimic led to an increased intracellular concentration of the chemotherapeutic agents and subsequent sensitivity to chemotherapeutic agents via direct targeting of the JNK2 gene. 39 The results of these studies support the hypothesis that reverting to an epithelial phenotype facilitates chemotherapy response and that the miR-200 family may have a therapeutic role in the management of advanced stage CRC.
Human studies
Diagnostics. The use of human clinical samples permits the assessment of heterogeneity within the population. It facilitates the investigation of the miR-200 family in the diagnosis and prognosis of patients with CRC. Human studies are summarized in Table 2 . progression. However, the regulatory mechanisms altering intra-tumoral miR-200 expression are still to be investigated.
Tumor tissue: miR-200b. The expression of miR-200b was significantly downregulated at the invasive front of tumors with degraded basement membranes when compared to normal and tumor core tissues (p 5 0.013 and p 5 0.05, respectively). However, in tumors with an intact basement membrane and in a sample of adenomas, no significant difference was observed. 41 Similarly, Knudsen et al. found that miR-200b expression was chiefly expressed at the epithelial surface, with decreasing expression in tumor budding cells and at the invasive front. The authors hypothesized that the presence of tumor budding cells represented a static image of the dynamic EMT process. 43 Diaz et al. demonstrated that miR-200b was significantly upregulated in tumor tissue versus that of normal adjacent tissue (n 5 127) (p < 0.0001). 40 Conversely, miR-200b was significantly downregulated in liver metastasis versus the matched primary tumor (n 5 54) (p 5 0.032). promoter region to be hypermethylated (p 5 0.04) in liver metastasis versus primary tumor. 20 These findings suggest that while the two miR-200 family clusters share similar seed sequences and should have similar functions, differential epigenetic regulation has a role in liver metastasis. The exact nature and extent of its role are still to be investigated.
Tumor tissue: miR-141. Feng et al. examined miR-141 expression in tumor tissue of patients with stage 1-3 cancer (n 5 56) and in normal controls (n 5 29). miR-141 expression was significantly decreased in the CRC samples compared to control samples (p < 0.01), and there was a further decrease in the miR-141 expression in patients with lymph node metastasis versus those with node-negative disease (p < 0.01). Interestingly, miR-141 expression was decreased in the lymph nodes of patients with node-negative disease when compared to controls. 46 Ye et al. had similar results where miR-141 was decreased in the primary tumor versus normal adjacent tissue in 6 of 8 cases. 38 In contrast to the previous two studies, Wu et al. found miR-141 to be significantly increased in tumor tissue versus normal adjacent tissue in 15/18 cases. 30 Similarly, Diaz et al. found miR-141 to be significantly upregulated in the tissue of tumor samples versus normal adjacent tissue (n 5 127) (p 5 0.036). 40 Hur et al. demonstrated that miR-141 expression was significantly greater in the liver metastasis than the primary tumor (p 5 0.0234). 20 The discrepancy in the above studies may be explained by the variation in RNA extraction methodology. Bojmar et al. used laser capture microdissection (LCM) as part of their methodologies and found that when total tumor tissue was used for RNA extraction, there was no difference in miR-141 expression between the control group and the primary tumor, and that there was a significant decrease in the expression in the liver metastasis versus the control group. However, with the use of LCM, miR-141 was significantly decreased in the primary tumor versus the controls, and there was no difference in colorectal liver metastasis versus controls (p 5 0.016). 47 In the future, investigators may need to consider the contribution of nontumor cells if they are using whole tissue in their studies.
Tumor tissue: miR-429. Sun et al. studied miR-429 expression in patients with stages 2 and 3 CRC and in normal adjacent tissue (n 5 50). miR-429 was significantly downregulated compared to normal tissue (p < 0.01). 29 Conversely, Diaz et al. found miR-429 to be significantly upregulated in tumor tissue versus normal adjacent tissue (n 5 127) (p < 0.0011). 40 No difference was observed in miR-429 expression between the primary tumor versus the matched liver metastasis. 20 Plasma/serum. Plasma/serum levels of the miR-200 family have been investigated as a potential biomarker for CRC. Plasma miR-200c was significantly greater in patients with CRC (p < 0.001) and was predictive of CRC with a sensitivity and specificity 64.1% and 73.3%, respectively. 48 Serum miR200c, miR-200b and miR-141 were significantly greater in patients with metastatic disease versus localized disease (p 5 0.015, p 5 0.031 and p 5 0.024, respectively), and their levels were positively correlated with the presence of liver metastasis. 42 Interestingly, the serum miR-141 was found to be downregulated in patients with stages 2 and 3 CRC versus normal controls. 46 Cheng et al. reported no significant difference in the serum levels between all-stage CRC (n 5 49 An important consideration for investigators using blood-based microRNA measurements is the methodology used as there can be significant variability in results. 50 Prognostic role of the miR-200 family. A number of authors have attempted to describe the prognostic function of the miR-200 family in both the tumor tissue and in blood samples of patients with CRC ( Table 3) .
As mentioned previously, Diaz et al. demonstrated that increased tissue expression of miR-200a (p 5 0.027), miR200c (p 5 0.042), and miR-429 (p 5 0.001) were associated with improved overall survival. On multivariate regression analysis, low tissue miR-429 expression was associated with a worse overall survival and disease-free survival (OR 5 3.540 95% CI: 2.355-19.040 p < 0.0001 and OR 5 5.884, 95% CI: 2.286-15.166, p < 0.0001, respectively). Interestingly, for patients with stage 2 disease, who received adjuvant chemotherapy (n 5 32) and had low tissue expression of miR-429 versus those with high miR-429 tissue expression, there was a worse overall survival (OR5 28.513, 95% CI: 2.708-300.254, p 5 0.005). 40 Similarly, low tissue miR-200a expression was associated with worse cancer-specific survival on univariate analysis in patients with CRC. This was validated in an external sample to the study authors' own patient cohort (HR 5 2.04, 95% CI:1.28-3.25, p 5 0.002). 51 Bhangu et al. demonstrated that low tissue miR-200c expression was associated with an increased T-tumor stage (p 5 0.029), poor response to chemotherapy (p < 0.001) and poor overall survival (p 5 0.01). However, this patient cohort may be inherently biased with 46.6% (48/103) of patients requiring a pelvic exenteration and 69% of patients receiving neoadjuvant chemo-radiotherapy. 52 There is significant interest in the development of bloodbased tests to assist in the diagnosis and management of . Some of this variation may be accounted for by, as the authors comment, the fact that the some of the blood samples were hemolyzed and that phlebotomy was performed at variable time-points in relation to the date of surgery and to adjuvant therapy. 53 Cheng et al. demonstrated that plasma miR-141 levels were associated with metastatic CRC and found to have a specificity of 89.7% and a sensitivity of 77.1% in differentiating metastatic from nonmetastatic CRC (n 5 258). In addition, on multivariate regression analysis, high circulating miR-141 was associated with poor overall survival (HR 5 2.4, 95% CI-1.18-4.86 p 5 0.016). 49 
Discussion
The aim of this systematic review is to examine the function of the miR-200 family in CRC reporting upon both in vitro and human studies. Specifically, we sought to elucidate the molecular mechanisms involved and identify the role of the miR-200 family in the diagnostic and therapeutic management of patients with CRC. This work complements other reviews on the role of microRNAs and the miR-200 family in cancer but focuses specifically on the miR-200 family in CRC.
EMT is recognized to be a critical component in tumor metastasis and the miR-200/ZEB/E-cadherin pathway is a central regulator of it. The feed-forward loop is a core element in the expression of the cellular phenotype. As previously mentioned, both ZEB1 and the miR-200 family members inhibit the expression of the other, signifying the importance of the initial signal in terms of the eventual epithelial or mesenchymal phenotype. There is, however, the potential for plasticity with epigenetic and gene regulation for switching between phenotypes.
In studying the relative expression of the miR-200 family between primary tumors and their associated metastases, the central role for miR-200 family regulation is recognized. Toiyama et al. demonstrated that while the serum expression of miR-200c increased with tumor stage, the primary tumor tissue expression decreased. They hypothesised that this difference was accounted for by the increased expression of miR200c by the metastatic tumor. 45 This suggests reversion to an epithelial phenotype facilitates tumor proliferation at the metastatic site. This occurs after the primary tumor has undergone EMT to facilitate initial tumor metastasis. The differential methylation status of the miR-200 promoter regions of liver metastasis may indicate a variable role for the miR-200 family in metastatic tumor progression but it does highlight the significant role that the miR-200 family has in tumor metastasis. 20 While gene expression of the miR-200 family can be modulated epigenetically, with transcription factors and with other co-stimulatory/inhibitory pathways, direct transfection with miR-200 family mimics can revert cell lines to an epithelial phenotype and reduce their invasive characteristics. Chemotherapy resistance is an important factor in the management of patients with CRC. In chemotherapeutic-resistant cell lines, which display mesenchymal characteristics, transfection with miR-200 mimics resulted in increased chemotherapeutic sensitivity. It is interesting to note that patients with decreased primary tissue expression of miR-429, miR200a and miR-200c had worse survival than patients with high microRNA expression. 40, 51, 52 This may be indicative of tumors having a mesenchymal phenotype, and thus having increased metastatic potential and worse outcomes. There may be a role for the miR-200 family in the future as a therapeutic modality since a number of microRNAs are already in early stage clinical trials. 54 There is a distinct relative difference within CRC in the intratumoral expression of miR-200 family members. Invasion of the basement membrane leads to differential expression of the miR-200 family at the invasive front, suggesting that the tumor has transitioned to a mesenchymal phenotype at that site to facilitate invasion and metastasis. However, in adenomas and tumors with intact basement membranes, there is no difference in the expression between intratumoral location, suggesting that a homogenous epithelial phenotype is expressed. Bojmar et al. used both total tissue and LCM in their methodology and highlighted the potential variation that may be seen when using clinical samples. While there was no difference in the expression of miR-141 between the normal tissue and primary cancer when total tissue was used, a significant decrease in the primary tissue was observed when LCM was used. The variable volume of stroma in the tissue samples can be a confounder in the expression of microRNAs, which may account for some of the aberrations in the study results described.
There is significant interest in the development of blood based diagnostic tests in CRC due to the current poor compliance with endoscopic and stool-based screening tests. A number of different microRNAs have been shown to be differentially expressed in patients with CRC versus healthy controls.
9 microRNA panel models for the detection of CRC are currently being developed. 55 miR-200c was individually shown to have good predictive values in the diagnosis of CRC. 48 In contrast, miR-141 was not significantly different from healthy controls but was significantly different between tumor stages and had good prediction values for distinguishing metastatic from nonmetastatic disease. 49 There were conflicting results on the prognostic value of miR-200c as a predictor for overall survival. 45, 53 Variability in the timing of serum sampling may be an important factor. Zhang et al. reported a significant decrease in the plasma levels of miR200c post CRC resection. 48 In conclusion, this systematic review describes the roles of miR-200 family in CRC. While the miR-200/ZEB1/E-cadherin axis has been well described in in vitro studies, modulation of this axis through epigenetic, transcriptional factor and other molecular pathway regulation are important areas of research. The clinical studies presented do suggest a role for the miR-200 family in the diagnosis and prognosis of patients with CRC but to elucidate a therapeutic role, further research needs to be done in characterizing intratumoral and intertumoral variability in miR-200 family expression and the molecular reasons behind same.
